Clinical Trials Logo

Glabellar Frown Lines clinical trials

View clinical trials related to Glabellar Frown Lines.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05517538 Completed - Wrinkle Clinical Trials

Split-face Study: Cosmetic Botulinum Toxin Type A Injection Under Electromyography-guidance Versus Conventional Palpation Technique

Start date: August 9, 2021
Phase: N/A
Study type: Interventional

The aim of this study was to compare between the conventional palpation method of botulinum toxin type A injection and the electromyography-guided method using clinical parameters and electromyography analysis.

NCT ID: NCT05364580 Completed - Clinical trials for Glabellar Frown Lines

The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines

Start date: March 6, 2023
Phase: Phase 3
Study type: Interventional

This study will be conducted in Phase Ⅲ clinical trials. In Phase Ⅲ, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at a total of 20U(4U/0.1mL each) in five sites of the glabellar lines. The investigational product is administered once, maintaining double-blind for a total of 16 weeks of observation. Thereafter, efficacy and safety are assessed by comparing with BOTOX® after regular visits conducted at 4,8,12 and 16 weeks.

NCT ID: NCT05321979 Completed - Clinical trials for Glabellar Frown Lines

Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

Start date: February 7, 2022
Phase: Phase 3
Study type: Interventional

This study is intended to evaluate long-term safety and efficacy of MBA-P01 in treatment of glabellar lines.

NCT ID: NCT05320393 Completed - Clinical trials for Glabellar Frown Lines

Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

Start date: March 30, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to demonstrate the safety and duration of effect of 40 Units of prabotulinumtoxinA-xvfs (Jeuveau®) in providing temporary improvement in the appearance of moderate to severe glabellar lines (frown lines, which are the vertical lines that develop between the eyebrows) in adult participants. It will also determine if the duration of effect of 40 Units of Jeuveau® is greater than that of 20 Units of Jeuveau® and 20 Units of Botox® Cosmetic.

NCT ID: NCT05277337 Completed - Clinical trials for Glabellar Frown Lines

Study Comparing Treatment With Alluzience vs Reconstituted Toxin

STAR
Start date: February 4, 2022
Phase: Phase 4
Study type: Interventional

This is a Phase IV, open-label, randomized, interventional, two-armed, multi-centre study to investigate subject treatment perception and Investigator treatment experience when using Alluzience or vacuum-dried botulinum neurotoxin type A (powder BoNT-A) for treatment of glabellar lines (GL).

NCT ID: NCT05217355 Completed - Clinical trials for Glabellar Frown Lines

A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

Start date: December 28, 2021
Phase: Phase 2
Study type: Interventional

This study is intended to evaluate the efficacy and safety of MBA-P01 compared to placebo in treatment of glabellar lines.

NCT ID: NCT05148000 Completed - Clinical trials for Glabellar Frown Lines

Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines

Start date: January 23, 2023
Phase: Phase 3
Study type: Interventional

This study to assess aesthetic improvement following treatment with QM1114-DP.

NCT ID: NCT05129319 Completed - Clinical trials for Glabellar Frown Lines

Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD

Start date: December 16, 2021
Phase: Early Phase 1
Study type: Interventional

This is a blinded, randomized study in the US to compare the duration response of two different concentrations of Jeuveau in healthy female subjects with moderate to severe dynamic glabellar lines on maximum frown.

NCT ID: NCT05059587 Completed - Clinical trials for Glabellar Frown Lines

Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines

Start date: August 30, 2021
Phase: Phase 3
Study type: Interventional

This study is intended to evaluate the efficacy and safety of MBA-P01 compared to BOTOX in treatment of glabellar lines.

NCT ID: NCT04996810 Completed - Clinical trials for Glabellar Frown Lines

The Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines

Start date: December 10, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study will be conducted in Phase I/II clinical trials. In Phase I, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at a total of 20U(4U/0.1mL each) in five sites of the glabellar lines. Safety is assessed after 12 weeks. In Phase II, subjects with moderate to severe glabellar lines are enrolled and will be injected the "PROTOXIN" or the "BOTOX®" at a total of 20U(4U/0.1mL each)in five sites of the glabellar lines. Thereafter, efficacy and safety are assessed by comparing with BOTOX®.